NEWS

Tempus Announces New Multi-omics Collaboration with Actuate Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc. (Actuate), a clinical-stage biopharmaceutical company, to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests wi...